N Müller1, T Heller1, M H Freitag2, B Gerste3, C M Haupt3,4, G Wolf1, U A Müller1. 1. Department of Internal Medicine III, Jena University Hospital, Jena, Germany. 2. Institute of General Practice and Family Medicine, Jena University Hospital, Jena, Germany. 3. Wissenschaftliches Institut der AOK (WIdO), Berlin, Germany. 4. Bundesanstalt für Arbeitsschutz und Arbeitsmedizin (BAuA), Berlin, Germany.
Abstract
AIMS: This population-based study assesses the healthcare utilization of people with Type 2 diabetes by analysing routine data from Allgemeine Orts-Krankenkasse (AOK), the largest statutory health insurance provider in Germany. METHODS: Anonymized billing data from all AOK-insured persons with at least one day of insurance during the evaluation year 2010 were analysed. Treatment and cost data from all areas of inpatient and outpatient care were available, as was information regarding patient age and sex. International Classification of Diseases (ICD-10) diagnosis and Anatomical Therapeutic Chemical (ATC) classification were used to identify 2.7 million insured persons with diabetes. RESULTS: The age- and sex-standardized prevalence of Type 2 diabetes was 9.8%. Of those patients identified, 33.9% had at least one diabetes-related complication and 83.0% had a diagnosis of hypertension. Almost two-thirds (63.1%) received antihyperglycaemic medication. Metformin and sulfonylurea were prescribed most often; medications without proof of benefit in endpoint studies were prescribed much less frequently. People without diabetes were admitted to hospital only half as often as those with Type 2 diabetes. The projected total expenditure in Germany for all people with Type 2 diabetes amounted to approximately €33.3 billion in 2010. CONCLUSIONS: This study shows an increase in both the prevalence of diabetes and treatment costs. The majority of people with Type 2 diabetes were aged 70 years or older. One third of this group has diabetes-related complications. Antihyperglycaemic medications without proof of benefit in endpoint studies were prescribed much less frequently than drugs with proof of benefit.
AIMS: This population-based study assesses the healthcare utilization of people with Type 2 diabetes by analysing routine data from Allgemeine Orts-Krankenkasse (AOK), the largest statutory health insurance provider in Germany. METHODS: Anonymized billing data from all AOK-insured persons with at least one day of insurance during the evaluation year 2010 were analysed. Treatment and cost data from all areas of inpatient and outpatient care were available, as was information regarding patient age and sex. International Classification of Diseases (ICD-10) diagnosis and Anatomical Therapeutic Chemical (ATC) classification were used to identify 2.7 million insured persons with diabetes. RESULTS: The age- and sex-standardized prevalence of Type 2 diabetes was 9.8%. Of those patients identified, 33.9% had at least one diabetes-related complication and 83.0% had a diagnosis of hypertension. Almost two-thirds (63.1%) received antihyperglycaemic medication. Metformin and sulfonylurea were prescribed most often; medications without proof of benefit in endpoint studies were prescribed much less frequently. People without diabetes were admitted to hospital only half as often as those with Type 2 diabetes. The projected total expenditure in Germany for all people with Type 2 diabetes amounted to approximately €33.3 billion in 2010. CONCLUSIONS: This study shows an increase in both the prevalence of diabetes and treatment costs. The majority of people with Type 2 diabetes were aged 70 years or older. One third of this group has diabetes-related complications. Antihyperglycaemic medications without proof of benefit in endpoint studies were prescribed much less frequently than drugs with proof of benefit.
Authors: Andrzej Śliwczyński; Melania Brzozowska; Andrzej Jacyna; Petre Iltchev; Tymoteusz Iwańczuk; Waldemar Wierzba; Michał Marczak; Katarzyna Orlewska; Piotr Szymański; Ewa Orlewska Journal: PLoS One Date: 2017-06-05 Impact factor: 3.240
Authors: Martin Röhling; Marcus Redaélli; Dusan Simic; Kristina Lorrek; Christina Samel; Paul Schneider; Kerstin Kempf; Stephanie Stock; Stephan Martin Journal: Diabetes Metab Syndr Obes Date: 2019-11-29 Impact factor: 3.168
Authors: Hannah König; A Rommel; Jens Baumert; Christian Schmidt; Hans-Helmut König; Christian Brettschneider; Alexander Konnopka Journal: BMJ Open Date: 2021-04-21 Impact factor: 2.692
Authors: Martin Busch; Jennifer Nadal; Matthias Schmid; Katharina Paul; Stephanie Titze; Silvia Hübner; Anna Köttgen; Ulla T Schultheiss; Seema Baid-Agrawal; Johan Lorenzen; Georg Schlieper; Claudia Sommerer; Vera Krane; Robert Hilge; Jan T Kielstein; Florian Kronenberg; Christoph Wanner; Kai-Uwe Eckardt; Gunter Wolf Journal: BMC Nephrol Date: 2016-06-11 Impact factor: 2.388
Authors: Rose J Geurten; Arianne M J Elissen; Henk J G Bilo; Jeroen N Struijs; Chantal van Tilburg; Dirk Ruwaard Journal: BMJ Open Date: 2021-12-07 Impact factor: 2.692